MOVANTIK Drug Patent Profile

Which patents cover Movantik, and when can generic versions of Movantik launch?

Movantik is a drug marketed by Averitas and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in forty-five countries.

The generic ingredient in MOVANTIK is naloxegol oxalate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.

DrugPatentWatch^® Generic Entry Outlook for Movantik

Movantik was eligible for patent challenges on September 16, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 16, 2028. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for MOVANTIK

International Patents:	90
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	32
Clinical Trials:	14
Patent Applications:	211
Drug Prices:	Drug price information for MOVANTIK
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOVANTIK
What excipients (inactive ingredients) are in MOVANTIK?	MOVANTIK excipients list
DailyMed Link:	MOVANTIK at DailyMed

See drug prices for MOVANTIK

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MOVANTIK

NDA:

204760

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MOVANTIK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Missouri-Columbia	Phase 4
University of Tennessee, Chattanooga	N/A
Camille Ladanyi MD	N/A

See all MOVANTIK clinical trials

Pharmacology for MOVANTIK

Drug Class	Opioid Antagonist
Mechanism of Action	Opioid Antagonists

Paragraph IV (Patent) Challenges for MOVANTIK

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MOVANTIK	Tablets	naloxegol oxalate	12.5 mg and 25 mg	204760	2	2018-09-17

US Patents and Regulatory Information for MOVANTIK

MOVANTIK is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No			Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes			Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No			Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes			Y	Y

Expired US Patents for MOVANTIK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014

International Patents for MOVANTIK

See the table below for patents covering MOVANTIK around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2002360284
Canada	2463938	CONJUGUES POLYMERES D'ANTAGONISTES OPIOIDES (POLYMER CONJUGATES OF OPIOID ANTAGONISTS)
Cyprus	1117608
Cyprus	1119906

Supplementary Protection Certificates for MOVANTIK

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1694363	122015000037	Germany		PRODUCT NAME: NALOXEGOL ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363	C300737	Netherlands		PRODUCT NAME: NALOXEGOL ALSMEDE DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363	CA 2015 00028	Denmark		PRODUCT NAME: OXYLATSALT AF NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141208
1694363	PA2015019	Lithuania		PRODUCT NAME: NALOXEGOLUM; REGISTRATION NO/DATE: EU/1/14/962 20141208

MOVANTIK (naloxegol) market dynamics and financial trajectory: pricing, demand drivers, exclusivity, and competitive pressures

Last updated: July 21, 2026

MOVANTIK (naloxegol) is a revenue-generating opioid-induced constipation (OIC) brand in a crowded class that includes PAMORAs. Its market position has shifted from post-launch growth to ongoing share competition driven by payer restrictions, segment-mix changes, and competitive breadth across oral and titration approaches. From an IP and entry-risk perspective, the key market question is not whether naloxegol remains formulary, but how fast payers steer patients toward competing PAMORAs once generics and branded alternatives pressure net price.

How has MOVANTIK performed financially since launch?

Short answer: Public financial disclosure is fragmented because naloxegol’s sales sit inside broader company reporting (Porter/US commercialization historically under a partner and later under Allergan/AbbVie and then a divided commercial structure across geographies). The durable way to model MOVANTIK’s trajectory is to track (1) US TRx and (2) US net price after payer contracting, both of which reflect class-level OIC constraints.

Core commercial mechanics for MOVANTIK

• Target population: OIC in adults with chronic non-cancer pain receiving opioids, plus later label scope aligned with OIC pathways and constipation management in opioid-treated patients.
• Adoption constraint: OIC programs require payer confidence that the drug reduces constipation while maintaining analgesia. That creates formulary friction and limits rapid switch to newer PAMORAs when payer preferred status shifts.
• Net price pressure: As class competition intensifies, PBM and commercial payer outcomes drive discounts and access terms.

What typically drives MOVANTIK revenue trend over time

• Share shift inside OIC: PAMORA market growth is capped by diagnosis and opioid prevalence trends, then redistributed by formulary placement.
• Step edits and prior authorization: These reduce script conversion and elongate time to reach maintenance demand.
• Patient persistence: Switching within PAMORAs is common when dosing tolerance is limited, or when stool frequency targets are not met.

What market dynamics affect MOVANTIK demand in opioid-induced constipation?

Short answer: MOVANTIK’s demand is driven by the opioid patient funnel and then by payer access, with competitive displacement within PAMORAs the dominant variable after initial adoption.

Which drivers increase demand for naloxegol (MOVANTIK)

• Opioid utilization trend: OIC volumes rise with more patients receiving long-term opioids.
• Chronic non-cancer pain management: Persistent prescribing for chronic pain sustains demand for OIC treatments.
• Preference for oral PAMORAs: Patient adherence and convenience influence script conversion.

Which factors reduce demand

• Payer preference migration: When competing PAMORAs become preferred or when contract terms worsen for MOVANTIK, TRx growth slows.
• Therapeutic switching: Clinicians may switch PAMORAs due to perceived onset, tolerability, or stool outcomes.
• Formulary tiering: Tier status and copay design impact persistence in insured populations.

Which companies compete with MOVANTIK in PAMORAs, and how does class competition shape pricing?

Short answer: MOVANTIK competes with other peripherally acting mu-opioid receptor antagonists (PAMORAs). The class typically trades pricing for formulary status, resulting in net price compression even when gross prescriptions stabilize.

Competitive set and positioning (US PAMORA landscape)

• Naloxegol (MOVANTIK): Oral PAMORA positioned for OIC with opioid-treated chronic non-cancer pain and related label populations.
• Naldemedine (SYMPROIC): Another oral PAMORA often used in payer-preference strategy.
• Methylnaltrexone: Includes subcutaneous formulations in some segments and can be used as a payer-controlled comparator.
• Alvimopan: Perioperative setting, not a direct chronic OIC substitute but can influence institutional constipation pathways.

Class dynamic that matters for finance

• When at least one oral PAMORA locks “preferred” status, it compresses the net price and share for non-preferred options, including MOVANTIK.

How do payer restrictions and formulary status affect MOVANTIK net revenue?

Short answer: OIC is a classic payer-managed category. MOVANTIK’s revenue elasticity depends on coverage rules, not just clinical differentiation.

Key payer levers

• Prior authorization and step therapy: Require trials of OTC laxatives or other constipation therapies before approval for PAMORAs.
• Quantity limits: Can limit duration or dosing flexibility.
• Copay support: Can temporarily protect adherence but becomes less effective when PBMs and plans negotiate down support.
• PBM rebates: Net price is structurally sensitive to rebating tied to formulary placement.

Market effect

• Even with stable patient demand, net sales can flatten due to contracting effects.

What is the patent and exclusivity backdrop for naloxegol that affects market risk?

Short answer: The question for MOVANTIK’s future is tied to (1) Orange Book-protected patents listed for the naloxegol drug product and (2) how quickly challengers can earn approval and launch based on patent carve-outs. The revenue risk rises when multiple patents expire or can be avoided via design-around.

Exclusivity timeline: what matters to business planning

• Composition-of-matter and method patents determine whether generics can launch under paragraph IV or require section viii carve-outs.
• Formulation or manufacturing patents can delay generic substitution even when active ingredient patent coverage weakens.
• Orange Book listings: These drive the litigation and launch sequencing risk.

What is the Orange Book status of MOVANTIK, and which patents are most material to generic entry?

Short answer: Orange Book listings identify specific naloxegol-drug product patents (and any related exclusivity) that constrain generic entry. The material patents for finance are those that remain listed on the drug product and can be the basis for paragraph IV litigation.

How to interpret patent lists for revenue exposure

• A high number of remaining listings at the time of ANDA filing usually increases:
  • probability of litigation,
  • probability of delayed launch,
  • probability that settlement terms extend market exclusivity.

Business relevance

• MOVANTIK’s financial trajectory is most sensitive to:
  • whether ANDAs are filed with paragraph IV certifications,
  • how many patents are successfully challenged,
  • whether any settlement includes “no-launch” or market-share protections.

When does naloxegol lose exclusivity, and how does that impact generic launch scenarios?

Short answer: Launch timing depends on the last expiring patent listed for the approved naloxegol drug product and on any negotiated settlements that create an effective entry barrier longer than statutory expiration.

Three generic entry scenarios typically used in forecasting

1. Single-patent carve-out success: Launch occurs at the earliest permitted date after the last actively litigated patent expires or is cleared.
2. Full barrier through settlement: Settlement delays entry beyond statutory expiration via delayed launch covenants.
3. Design-around formulation: Market entry requires a different formulation or manufacturing method, shifting risk to additional patents and potential enforcement.

What patent litigation affects MOVANTIK, including paragraph IV challenges and settlements?

Short answer: Paragraph IV litigation is the critical event for forecast accuracy because it determines the probability of early generic launch, the effective “payoff” date in settlement terms, and the timing of loss of branded exclusivity.

Litigation events that drive the revenue cliff risk

• ANDA filing dates: When challengers signal potential launch timing.
• Court decisions: When invalidity or non-infringement rulings remove barriers.
• Settlement agreements: When entry is delayed in exchange for consideration, market segmentation, or licensing restrictions.

Why this matters for MOVANTIK financial trajectory

• If a settlement defers entry, MOVANTIK can monetize its installed base longer.
• If courts clear key patents quickly, net sales can compress after launch through substitution and PBM switching.

How does MOVANTIK compare with competing PAMORAs on market penetration and utilization?

Short answer: Market penetration within OIC is driven less by mechanism and more by access. Comparative outcomes in real-world utilization generally track preferred positioning, copay design, and PA friction.

Commercial comparison metrics used by payers and analysts

• TRx growth vs class average
• Share of prescriptions within PAMORAs
• Persistence and switch rates
• Formulary tier placement
• Net-to-gross discounts and rebate intensity
• Discontinuation rates due to tolerability

What manufacturing or delivery-formulation changes can create additional IP barriers for generics?

Short answer: Even when composition patents expire, generics can be blocked by formulation, manufacturing, or stability-related patents. For MOVANTIK, any drug-product-specific patents are commercially relevant because they can delay substitution and protect branded revenues.

Generic entry friction points

• Drug release characteristics that support perceived efficacy or tolerability
• Stability and shelf-life specifications affecting approval or commercialization readiness
• Process patents that create enforcement risk even if the active ingredient is cleared

How would a generic launch scenario for MOVANTIK affect revenues, margins, and market share?

Short answer: The financial impact is typically rapid and non-linear. Net sales often fall quickly after generic entry due to PBM switching, higher substitution, and rebate renegotiations.

Forecast structure for post-entry decline

• Year 0-1 decline: Largest share loss occurs immediately after formulary switching and coverage normalization.
• Year 1-3 stabilization: After early substitution, decline rates slow but remain pressure-heavy.
• Discounting: Brand manufacturers often increase rebates or shift support to protect adherence, compressing margins.

What is the investment and valuation relevance of MOVANTIK’s financial trajectory?

Short answer: Investors typically treat branded OIC portfolios as “high visibility but time-limited.” MOVANTIK valuation sensitivity is dominated by:

• probability-weighted generic entry timing,
• magnitude of net price after payer renegotiation,
• persistence in the absence of preferred status.

Key Takeaways

• MOVANTIK’s market trajectory in OIC is primarily driven by payer access mechanics, not by MoA differentiation alone.
• Competitive pressure from other PAMORAs shapes net price through formulary status and rebate intensity.
• Patent and Orange Book-listed drug-product barriers determine generic entry timing and the probability of revenue cliffs.
• Financial modeling should treat post-launch and post-ANDA events as probabilistic, with litigation and settlement outcomes as primary drivers of effective exclusivity.

FAQs

1. How do PBM formulary changes typically affect MOVANTIK TRx growth?
2. What are the most common reasons clinicians switch between naloxegol and other PAMORAs?
3. How do paragraph IV filings change the expected revenue timeline for MOVANTIK?
4. What Orange Book patent categories most often delay generic substitution for branded oral drugs like MOVANTIK?
5. How does OIC patient persistence influence longer-term MOVANTIK net sales after competitive entry?

References

1. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. FDA. Drug Approval Package for MOVANTIK (naloxegol). FDA.

DrugChatter Q&A for MOVANTIK

Does medicare cover movantik?
Movantik generic availability 2026?
Movantik 25 mg tablet price?
Why is movantik so expensive?
What is movantik used for?